The University of Chicago Header Logo

Connection

Stephen Kent to Antibodies, Neutralizing

Back to Details
This is a "connection" page, showing publications Stephen Kent has written about Antibodies, Neutralizing.
Stephen Kent
Connection Strength
6.054
Antibodies, Neutralizing
  1. Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. EBioMedicine. 2021 Aug; 70:103518.
    View in: PubMed
    Score: 0.642
  2. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol Cell Biol. 2020 04; 98(4):253-263.
    View in: PubMed
    Score: 0.578
  3. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J Clin Invest. 2019 01 02; 129(1):182-191.
    View in: PubMed
    Score: 0.533
  4. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses. 2018 06 18; 10(6).
    View in: PubMed
    Score: 0.517
  5. HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends Immunol. 2018 05; 39(5):359-366.
    View in: PubMed
    Score: 0.503
  6. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Sci Transl Med. 2017 Aug 09; 9(402).
    View in: PubMed
    Score: 0.487
  7. Influenza-Specific Antibody-Dependent Phagocytosis. PLoS One. 2016; 11(4):e0154461.
    View in: PubMed
    Score: 0.445
  8. Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines. JCI Insight. 2025 Jan 09; 10(4).
    View in: PubMed
    Score: 0.204
  9. Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy - a balancing act. Front Immunol. 2023; 14:1307398.
    View in: PubMed
    Score: 0.188
  10. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat Rev Immunol. 2023 03; 23(3):135-136.
    View in: PubMed
    Score: 0.179
  11. Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano. 2022 08 23; 16(8):11769-11780.
    View in: PubMed
    Score: 0.171
  12. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine. 2021 Dec; 74:103729.
    View in: PubMed
    Score: 0.164
  13. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Rep. 2021 10 12; 37(2):109822.
    View in: PubMed
    Score: 0.162
  14. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight. 2021 08 23; 6(16).
    View in: PubMed
    Score: 0.161
  15. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 05 11; 118(19).
    View in: PubMed
    Score: 0.158
  16. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020 09; 26(9):1428-1434.
    View in: PubMed
    Score: 0.149
  17. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Hum Gene Ther. 2018 09; 29(9):1011-1028.
    View in: PubMed
    Score: 0.131
  18. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat Commun. 2018 07 10; 9(1):2669.
    View in: PubMed
    Score: 0.130
  19. Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Hum Vaccin Immunother. 2017 11 02; 13(11):2726-2737.
    View in: PubMed
    Score: 0.123
  20. Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles. Vaccine. 2025 02 06; 46:126668.
    View in: PubMed
    Score: 0.051
  21. Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression. PLoS Pathog. 2024 Dec; 20(12):e1012739.
    View in: PubMed
    Score: 0.051
  22. Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster. EBioMedicine. 2023 Dec; 98:104878.
    View in: PubMed
    Score: 0.047
  23. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat Immunol. 2023 06; 24(6):966-978.
    View in: PubMed
    Score: 0.045
  24. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine. EBioMedicine. 2023 Jun; 92:104574.
    View in: PubMed
    Score: 0.045
  25. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity. 2023 04 11; 56(4):879-892.e4.
    View in: PubMed
    Score: 0.045
  26. Current and future nanoparticle vaccines for COVID-19. EBioMedicine. 2021 Dec; 74:103699.
    View in: PubMed
    Score: 0.041
  27. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020 10; 5(10):1185-1191.
    View in: PubMed
    Score: 0.038
  28. Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. Front Immunol. 2019; 10:1025.
    View in: PubMed
    Score: 0.034
  29. Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. J Infect Dis. 2018 09 22; 218(9):1383-1393.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.